1058. Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated S. aureus Bloodstream Infection. (26th November 2018)
- Record Type:
- Journal Article
- Title:
- 1058. Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated S. aureus Bloodstream Infection. (26th November 2018)
- Main Title:
- 1058. Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated S. aureus Bloodstream Infection
- Authors:
- Cao, Yi
Guimaraes, Alessander
Hong, Kyu
Mayba, Oleg
Peck, Melicent
Gutierrez, Johnny
Ruffin, Felicia
Carrasco-Triguero, Montserrat
Dinoso, Jason
Clemenzi-Allen, A Asa
Koss, Catherine
Maskarinec, Stacey A
Chambers, Henry F
Fowler Jr., Vance G
Baruch, Amos
Rosenberger, Carrie - Abstract:
- Abstract: Background: Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes in patients with S. aureus bacteremia. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes. Methods: We conducted an observational study ( n = 32) to evaluate the prognostic value of circulating protein biomarkers for mortality and persistent bacteremia in patients with S. aureus bloodstream infections. A case–control study of 124 patients with complicated confirmed S. aureus bloodstream infections was used to validate our findings in the observational study. Results: We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia by multiple comparisons. Further statistical modeling identified IL-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers having the best power to classify fatal outcome. Baseline IL-17A levels were elevated in patients withAbstract: Background: Staphylococcus aureus is a leading cause of bacteremia, yet there remains a significant knowledge gap in the identification of relevant biomarkers that predict clinical outcomes in patients with S. aureus bacteremia. Heterogeneity in the host response to invasive S. aureus infection suggests that specific biomarker signatures could be utilized to differentiate patients prone to severe disease, thereby facilitating earlier implementation of more aggressive therapies. To further elucidate the inflammatory correlates of poor clinical outcomes in patients with S. aureus bacteremia, we evaluated the association between a panel of blood proteins at initial presentation of bacteremia and disease severity outcomes. Methods: We conducted an observational study ( n = 32) to evaluate the prognostic value of circulating protein biomarkers for mortality and persistent bacteremia in patients with S. aureus bloodstream infections. A case–control study of 124 patients with complicated confirmed S. aureus bloodstream infections was used to validate our findings in the observational study. Results: We identified 13 candidate proteins that were correlated with mortality and persistent bacteremia by multiple comparisons. Further statistical modeling identified IL-8 and CCL2 as the strongest individual predictors of mortality, with the combination of these biomarkers having the best power to classify fatal outcome. Baseline IL-17A levels were elevated in patients with persistent bacteremia, endovascular and metastatic tissue infections. Conclusion: The results demonstrate the potential utility of selected biomarkers to distinguish patients with the highest risk for treatment failure and bacteremia-related complications, providing a valuable tool for clinicians in the management of S. aureus bacteremia. Additionally, these biomarkers could identify patients with the greatest potential to benefit from novel therapies in clinical trials. Disclosures: All authors: No reported disclosures. … (more)
- Is Part Of:
- Open forum infectious diseases. Volume 5(2018)Supplement 1
- Journal:
- Open forum infectious diseases
- Issue:
- Volume 5(2018)Supplement 1
- Issue Display:
- Volume 5, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 5
- Issue:
- 1
- Issue Sort Value:
- 2018-0005-0001-0000
- Page Start:
- S316
- Page End:
- S316
- Publication Date:
- 2018-11-26
- Subjects:
- Communicable diseases -- Periodicals
Medical microbiology -- Periodicals
Infection -- Periodicals
616.9 - Journal URLs:
- http://ofid.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/ofid/ofy210.895 ↗
- Languages:
- English
- ISSNs:
- 2328-8957
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21962.xml